Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
A RETROSPECTIVE case series has identified ophthalmic complications in patients using the antidiabetic drugs semaglutide and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback